Market Research Blog – Page 9 – New Product Development

Global Cocaine Intoxication Treatment Market to Reach USD 17.91 Million by 2033, Driven by Rising Awareness and Advancements in Treatment Options | FMI

The global cocaine intoxication treatment market is poised for significant growth, with market value expected to increase from USD 10 Million in 2023 to an impressive USD 17.91 Million by 2033, registering a robust CAGR of 6% during the forecast period (2023-2033). This is a marked improvement from the 4% CAGR recorded during the historical period of 2018-2022, signaling a shift in the landscape of treatment options and healthcare interventions for cocaine intoxication.

Key Drivers of Market Growth:

Rising Prevalence of Cocaine Use

With increasing awareness of substance abuse disorders globally, the need for effective treatments to combat cocaine intoxication has become critical. Healthcare systems are increasingly focused on addressing this issue through enhanced treatment protocols.

Advancements in Pharmaceutical Research

Innovation in pharmacological treatments and supportive therapies is anticipated to drive demand. New drug formulations and therapeutic strategies are gaining traction, contributing to market expansion.

Government and Non-Governmental Efforts

Proactive initiatives by government bodies and non-profit organizations are fostering the adoption of treatments, facilitating early interventions and access to care.

Regional Insights:

North America continues to dominate the market, owing to advanced healthcare infrastructure, high awareness levels, and government support.
Europe follows closely, with increasing investments in substance abuse treatment programs.
Emerging markets in Asia-Pacific and Latin America are witnessing growing demand, driven by rising prevalence and improving healthcare accessibility.

The Cocaine Intoxication Treatment Market features a mix of established players and emerging innovators. Companies are focusing on R&D, collaborations, and strategic partnerships to strengthen their market presence.

Future Outlook:

As healthcare systems globally recognize the growing challenge of substance abuse, the Cocaine Intoxication Treatment Market is expected to witness sustained growth. Stakeholders in the pharmaceutical and healthcare sectors are well-positioned to capitalize on this opportunity, delivering effective solutions to address this pressing issue.

Increased Market Attention: Delve into Detailed Trends and Analysis with Our Report!

Key Takeaways from the Market Study:

The Cocaine Intoxication Treatment market expanded at a CAGR of 4% from 2018 to 2022.
From 2023 to 2033, the market for treating cocaine intoxication is projected to expand at a 6% CAGR.
The market for treating cocaine intoxication is anticipated to reach USD17.91 million by 2033.
Hospital pharmacies hold the biggest market share, per the FMI research.
For the Cocaine Intoxication Treatment market, North America is anticipated to have a 40% market share. With a share of 20% throughout the projection period, it is expected that the East & South Asia market would grow considerably.
The East & South Asia market is predicted to increase significantly throughout the forecast period, with a share of 20% during the forecast period.

“A series of international level collaborations involving healthcare stakeholders across various institutional settings are fueling further clinical trials and research studies dedicated to discovering Cocaine Intoxication Treatment.” says an FMI analyst

Market Competition:

Key players in the market include pharmaceutical companies such as Tonix Pharmaceutical, GlaxoSmithKline Plc., Bristol Myers Squibb Company, Pfizer Inc., Novartis AG, Teva Pharmaceuticals Ltd., Zydus Pharmaceuticals, Inc., Sun Pharmaceuticals Industries Ltd., and Advanz Pharmaceuticals, along with healthcare providers and technology companies among other global players.

Tonix Pharmaceuticals Holding Corp. was awarded a grant in August 2022 by the National Institute on Drug Abuse to aid the advancement of TNX-1300, a recombinant enzyme that targets the treatment of cocaine intoxication. Cocaine abuse can have harmful impacts on multiple bodily systems, primarily the cardiovascular system, and can lead to fatal consequences. TNX-1300 has been demonstrated to counteract the physiological consequences of intravenous cocaine use in previous clinical research. This grant will assist in the ongoing development of TNX-1300 as a treatment for life-threatening cocaine intoxication, which was responsible for more than 24,900 drug overdose fatalities in the United States in 2021.

Key Segments Profiled in the Cocaine Intoxication Treatment Industry Survey

Drug Class:

Phentolamine
Lorazepam
Diazepam
Verapamil
Morphine

Route of Administration:

Oral
Inhalation
Intravenous
Nasal

Distribution Channel:

Hospital Pharmacy
Retail Pharmacy
Online Pharmacy

Region:

North America
Latin America
Europe
East Asia
South Asia
Oceania
Middle East & Africa

About Future Market Insights (FMI)

Future Market Insights, Inc. (ESOMAR certified, recipient of the Stevie Award, and a member of the Greater New York Chamber of Commerce) offers profound insights into the driving factors that are boosting demand in the market. FMI stands as the leading global provider of market intelligence, advisory services, consulting, and events for the Packaging, Food and Beverage, Consumer Technology, Healthcare, Industrial, and Chemicals markets. With a vast team of over 400 analysts worldwide, FMI provides global, regional, and local expertise on diverse domains and industry trends across more than 110 countries.

Contact Us:

Future Market Insights Inc.
Christiana Corporate, 200 Continental Drive,
Suite 401, Newark, Delaware – 19713, USA
T: +1-347-918-3531
For Sales Enquiries: sales@futuremarketinsights.com
Website: https://www.futuremarketinsights.com
LinkedIn| Twitter| Blogs | YouTube

Global Serum Lactate Testing Market Set to Witness Robust Growth, Expected to Reach USD 491.7 Million by 2033

The global serum lactate testing market is poised for remarkable growth, with its current valuation standing at USD 193.8 million in 2023. Over the next decade, the market is projected to grow at an impressive CAGR of 8.9%, reaching an estimated worth of USD 491.7 million by 2033.

Serum lactate testing plays a pivotal role in diagnosing and monitoring critical conditions, including sepsis, hypoxia, and metabolic disorders. The increasing prevalence of these conditions, coupled with advancements in point-of-care diagnostic technologies, is driving the demand for efficient serum lactate testing solutions globally.

Key Growth Drivers:

Rising Incidence of Critical Illnesses: The growing global burden of sepsis and related complications has heightened the demand for serum lactate tests as a standard diagnostic tool.
Technological Advancements: Innovations in diagnostic devices, such as portable and automated analyzers, are enabling faster and more accurate test results, boosting market adoption.
Increased Awareness and Preventive Healthcare Practices: Growing awareness among healthcare providers and patients about the benefits of early diagnosis is fueling market expansion.

Market Outlook:

The forecasted growth reflects a significant shift in healthcare priorities, with increasing investments in diagnostics to improve patient outcomes. Emerging markets, particularly in Asia-Pacific and Latin America, are expected to offer lucrative opportunities due to their expanding healthcare infrastructure and rising healthcare expenditure.

As the healthcare industry continues to prioritize early and accurate diagnostics, the global serum lactate testing market is set to play a critical role in enhancing patient care outcomes. Market players are encouraged to focus on innovation, strategic collaborations, and market expansion to tap into the growing demand.

Key Takeaways:

The market is predicted to be widespread at a phenomenal pace due to a surge in athletics and sports activities, creating a huge opportunity for market players to step into the market.
As a matter of fact, athletes and sportspersons require to check their lactate levels throughout the training process or a race because at that time the lactate flows to various parts of the body, including the bloodstream.
Serum lactate testing shows accurate levels of lactate, as it is in an equilibrium state in the body. The rise in sports activities and participation of individuals in these activities increases the number of participants who would need to test their lactate levels, as a surge in the level of lactate in the blood could lead to adverse effects in the body.
Appropriate lactate measures are considered markers for accessing the conditioning of the energy systems which aid in predicting the race performance. Hence, a trainer needs to test and measure the lactate levels of a performer.
A significant surge in athletic and sports activities drives the need and usage of lactate meters in order to test lactate levels before and during the performance. Hence, an increase in sports activities presents lucrative opportunities in the market during the assessment period.

Heightened Market Interest: Our Complete Report Delivers Extensive Analysis and Trends!

Competitive Landscape:

Prominent companies in the serum lactate testing market are focusing on adopting key differentiating strategies such as increasing product pipelines and regulatory approvals, expanding into other regions, and brand management approvals in different regions. Because of increased awareness, the market’s dynamics have shifted.

Recent Development:

In March 2021, Roche finalized a merger agreement with GenMark Diagnostics, Inc., aiming to leverage innovative technologies that enable testing for multiple infections using a single patient sample.
In June 2021, Nova Biomedical introduced the Stat Profile Prime Plus blood gas analyzer, featuring a new critical care parameter designed to rapidly calculate and report mean corpuscular hemoglobin concentration.
In July 2021, Liverpool FC partnered with EFK Diagnostics through a contract for lactate kits.

Key Companies Profiled:

F. Hoffmann-La Roche AG
Nova Biomedical
COSMED srl
ApexBio
Arkray, Inc.
EFK Diagnostics
Sensa Core Medical Instrumentation Pvt. Ltd.
TaiDoc Technology
BST Biosensor Technology
Analox Instruments Limited
Marshal Scientific LLC

Key Market Segments Covered in the Serum Lactate Testing Industry Research

Product:

Table Top Analyzers
Hand-Held Meters
Test Strips

Application:

Medical Intervention
- Hypoxia
- Obstetrics
- Post Surgery Infection
- Other
Sports Application
Veterinary Application

End User:

Hospitals
Diagnostic Laboratories
Sports Institutes
Specialty Clinics
Home Care Settings

Region:

North America
Latin America
Europe
South Asia
East Asia
Oceania
The Middle East and Africa (MEA)

About Future Market Insights (FMI)

Contact Us:

Global Instrument Detergents for Manual Cleaning Market to be valued at USD 653.7 Million by 2033 Due to Rising Necessity for Reusable Medical Equipment | FMI

The global instrument detergents for manual cleaning market are projected to create a healthy CAGR of 3.9% from 2023 to 2033. The global market was valued at around USD 653.7 Million in 2033 reaching up from USD 428.3 Million in 2022. According to a recent study by Future Market Insights, enzymatic detergents are leading the market with a share of about 70.6% in the year 2022, within the global market.

The global demand for instrument detergents for manual cleanings is on the surge attributed to the propelling rates of surgeries and awareness in the prevention of infectious diseases. The demand for the market will expand over the forecast period because of the rising awareness of the hazardous hospital-acquired disease and the necessity for reusable medical equipment and devices. Owing to the stringent cleanliness regulations and higher standards for hygiene, the demand for detergent has been gradually rising in recent years and is anticipated to continue growing throughout the forecast period.

The market value for instrument detergents for manual cleaning was approximately 18.6% within the overall USD 2.3 Billion of the global medical device cleaning market in 2022. Within hospitals, a variety of medical devices are used while operating on patients or performing surgeries. Before and after each use, this medical equipment needs to be sanitized and cleaned. Most manufacturers understand the advantages of instrument detergents, which is driving them to focus more on the development of enzymatic formulations of detergents to meet the increasing demand for instrument detergents in the global market.

Key Takeaways:

At the global level, the rising number of surgeries and endoscopic procedures are the primary driving factors for the global market. Furthermore, changes in the lifestyles of consumers all over the region are leading to a rise in the number of lifestyle-associated diseases such as cancer and heart ailments. An increase in the prevalence of such diseases has led to a rise in the number of surgeries.
A surge in the geriatric population has resulted in a high number of surgeries comprising knee replacement and cataract operations, among others. Furthermore, the augmentation in the number of surgeries is expected to have a positive impact on the market.
As the number of surgeries increases, the demand for cleaning processes will also increase. For example, as per “Dobson GP. Trauma of major surgery: A global problem that is not going away. Int J Surg. 2020”, 310 million major surgeries are carried out every year throughout the entire world.
Manufacturers concentrate on the production of enzymatic detergents. Healthcare benefits and significant cost savings result from investing more money in multi-enzymatic detergents that are effectively formulated and validated, which create enzymatic detergents in the instrument detergent category, the top choice for most end users.
Due to all these positive factors, the demand for instrument detergents is rising exponentially. Due to all these positive factors, the demand for instrument detergents is rising exponentially.

Increased Market Insight Demand: Get Thorough Analysis and Trends in Our Complete Report!

Competitive Landscape:

The global market for instrument detergents for manual cleaning is consolidated, with a few established competitors. These businesses are employing strategies including mergers and acquisitions, partnerships, collaborations, and new product launches to satisfy consumer demand and increase their client base. Regional governments take initiative to invest in instrument detergents for manual cleaning equipment.

More Insights into the Global Instrument Detergents for Manual Cleaning Market

The North American market is anticipated to dominate the global instrument detergents for manual cleaning market. The U.S.A. accounted for around 94.2% of the total market share in 2022 and is expected to continue to experience the same growth throughout the forecast period. In the USA the market is expanding as the population of older people is increasing rapidly.

Japan is another market that exhibited lucrative growth of around 44.5% in 2022, with a market value of USD 27.1 Million in the East Asia instrument detergents for manual cleaning market 2022.

Top manufacturers in Japan supply instrument detergents at a lower cost. Local players manufacture instrument detergents at high volumes as compared to other global players.

Domestic key players that specialize in instrument detergents for manual cleaning are growing significantly to meet the expected rise in demand for instrument detergents. Manufacturers supply instrument detergents to local hospitals and ambulatory surgical centers at lower costs, and this factor will boost the market expansion in Japan. Therefore, demand within the market is rapidly increasing in Japan.

Key Companies Profiled:

STERIS Plc
Ecolab
Getinge Group
Serchem Ltd.
Ruhof
Medline
Advanced Sterilization Products
Schülke & Mayr GmbH
Medalkan
Metrex Research
Dr. Weigert
Boston Scientific Corporation
Enzyme Solutions Incorporated
Falconfire Inc.
BeliMed
Crosstex International, Inc.
Amity International

Key Market Segments Covered in Instrument Detergents for Manual Cleaning Industry Research:

By Detergent:

Enzymatic Detergents
Neutral Detergents
Acidic Detergents
Alkaline Detergents

By Instrument:

Surgical instruments
Endoscopes

By End User:

Hospitals
Ambulatory Surgical Centers
Diagnostic Centers
Specialty Clinics
Others

About Future Market Insights (FMI)

Contact Us:

Increasing Incidence of Whim Syndrome Management Market to Propel the Growth at 6% CAGR through 2033: FMI Study

The global whim syndrome management market is currently in its infancy, but it is expected to grow significantly in the coming years. The increasing prevalence of Whim Syndrome, coupled with the growing demand for effective treatment options, is driving the growth of this market. According to a new market research report published by Future Market Insights, the global Whim syndrome management market is projected to reach a value of USD 10 million by 2023, growing at a CAGR of 6% during the forecast period, surpassing USD 17.91 Million valuation by 2033.

One of the key factors driving the growth of the Whim syndrome management market is the increasing prevalence of this rare genetic disorder. Although Whim Syndrome is a rare disorder, the incidence of this condition is increasing. According to the National Organization for Rare Disorders (NORD), the incidence of Whim Syndrome is estimated to be around 1 in every 50,000 to 100,000 people worldwide.

Another factor driving the growth of the Whim syndrome management market is the increasing demand for effective treatment options. Currently, there are no approved treatments for Whim Syndrome. However, several companies are developing potential therapies for this rare disorder, and many of these treatments are in the late stages of clinical development.

In conclusion, the Whim syndrome management market is expected to grow significantly in the coming years, driven by the increasing prevalence of this rare genetic disorder and the growing demand for effective treatment options. As more treatments become available for Whim Syndrome, the demand for these treatments is expected to increase, driving the growth of this market.

Key Takeaways from the Market Study:

From 2018 to 2022, the whim syndrome management market grew at a CAGR of 4%.
The global Whim syndrome management market is expected to grow with a 6% CAGR during 2023 to 2033.
As of 2033, the Whim syndrome management market is expected to reach USD 17.91 Million.
According to the FMI analysis, hospital pharmacies account for the largest market share.
North America is expected to possess 40% market share for the Whim syndrome management market.
The East & South Asia market is predicted to increase significantly throughout the forecast period, with a share of 20% during the forecast period.

“A series of international level collaborations involving healthcare stakeholders across various institutional settings are fuelling further clinical trials and research studies dedicated to discovering Whim Syndrome Management.” opines Sabyasachi Ghosh Associate Vice President at Future Market Insights (FMI) analyst.

Growing Market Interest: Explore Comprehensive Insights and Trends with Our Detailed Report!

Market Competition:

Key players in the market include pharmaceutical companies such as X4 Pharmaceuticals, National Institute of Allergy and Infectious Diseases, GSK plc, Bristol Myers Squibb Company, F-Hoffmann La Roche Ltd., Pfizer Inc., Johnson and Johnson Services, Inc., Horizon Therapeutics plc, Amgen, and Leadiant Biosciences along with healthcare providers and technology companies among other global players.

Under the guidance of Philip Murphy, M.D. and David McDermott, M.D., researchers from the IRP have identified and enrolled three patients with advanced WHIM syndrome, who were ineligible for standard treatment, in an open-label study. These patients were administered low doses of plerixafor, and all three experienced a reduction in infection frequency and a significant enhancement in their quality of life. The utilization of plerixafor to treat WHIM syndrome is a new approach for patients who are unable to manage their symptoms using traditional therapies. Consequently, a randomized, double-blind Phase 3 trial has been developed to compare plerixafor to standard treatment, evaluate its clinical effectiveness, and gather additional safety information. You can find this trial on ClinicalTrials.gov with the identifier NCT02231879.

Key Segments Profiled in the Whim Syndrome Management Industry Survey:

Drug Class:

Mavorixafor
Plerixafor

Route of Administration:

Oral
Parenteral
Injectable

Distribution Channel:

Hospital Pharmacy
Retail Pharmacy
Online Pharmacy

Region:

North America
Latin America
Europe
East Asia
South Asia
Oceania
Middle East & Africa

About Future Market Insights (FMI)

Contact Us:

Atypical Hemolytic Uremic Syndrome (aHUS) Treatment Market to Register 4.9% CAGR from 2023 to 2033: FMI Study

During the forecast period 2023 to 2033, the atypical hemolytic uremic syndrome (ahus) treatment market is expected to grow at a value of 4.9% CAGR, according to Future Market Insights. By the year 2033, the global market for Atypical hemolytic uremic syndrome (ahus) treatment is expected to rise up to a market valuation of USD 2308.84 Million. Growth of the market can be attributed to increasing prevalence of the disease, rising awareness among healthcare professionals, and the introduction of innovative therapies that offer improved efficacy and safety profiles.

The market for aHUS treatment is also benefiting from increasing awareness of the disease among healthcare professionals and patients. As more physicians become familiar with the symptoms and diagnosis of aHUS, patients are more likely to receive a timely and accurate diagnosis, which can improve their chances of a favorable outcome.

In addition, pharmaceutical companies are investing in research and development of new therapies for aHUS, which is leading to the introduction of new treatments with improved efficacy and safety profiles. This is creating a competitive landscape for aHUS treatment, with companies vying for market share through the development of innovative therapies and effective marketing strategies.

Key Takeaways from the Market Study:

The Atypical hemolytic uremic syndrome (ahus) treatment market is expected to grow at a value of 4.9% CAGR in the forecast period 2023-3033.
By distribution channel, hospitals are expected to hold 45% of the market share in 2023 for Atypical hemolytic uremic syndrome (ahus) treatment market.
North America is expected to possess 44% market share for Atypical hemolytic uremic syndrome (ahus) treatment market in 2023.
Europe Atypical hemolytic uremic syndrome (ahus) treatment market size is expected to possess 38% market share in 2023.

“The market is also likely to benefit from the growing demand for personalized medicine, as patients with aHUS may require different treatment approaches based on their individual genetic and medical profiles.” states an FMI analyst

Enhanced Market Demand! Discover Thorough Trends and Insights in Our Complete Report!

Competitive Landscape:

Key players in the atypical hemolytic uremic syndrome (ahus) treatment market are Alexion Pharmaceuticals, Omeros Corporation, Novartis Pharmaceuticals, Hoffmann-La Roche, Chugai Pharmaceutical, Tasly Biopharmaceuticals, Prestige BioPharma, Abbott Medtronic, Teva Pharmaceuticals Ltd., Zydus Pharmaceuticals, Inc.

Omeros Corporation, a key player in the atypical hemolytic uremic syndrome (ahus) treatment market is offering narsoplimab (also known as OMS721), which is a first-in-class monoclonal antibody that targets the lectin pathway of the complement system. The lectin pathway is one of the three pathways in the complement system that can become overactivated in patients with aHUS.
Novartis has been involved in research into other potential treatments for aHUS. One of the most promising of these is iptacopan (LNP023), a first-in-class oral inhibitor of the complement system.

Key Segments Profiled in the Atypical Hemolytic Uremic Syndrome (aHUS) Treatment Industry Survey:

Product Type:

Mono
Combination
Mono/Combination

Molecule Type:

Monoclonal Antibody
Peptides

Polymer:

Small molecule
Gene therapy

Route of Administration:

Oral
Parenteral
Intravenous
Subcutaneous
Topical

Distribution Channel:

Hospital Pharmacy
Retail Pharmacy
Online Pharmacy

Region:

North America
Latin America
Europe
South Asia
East Asia
Oceania
MEA

About Future Market Insights (FMI)

Contact Us:

Growing Preference for Discrete Analyzers over Flow Analyzers Is Uplifting the Discrete Analyzers Market to reach a valuation of ~USD 2.6 Billion by the year 2033: Future Market Insights

According to Future Market Insights’ latest industry analysis, the market size for the global discrete analyzers market is expected to reach USD 1.5 Billion in 2023. It is projected to exhibit growth at a CAGR of 5.2% over the forecast period, with an estimated market size of ~USD 2.6 Billion by 2033.

High levels of air pollution and nutrient discharges from agriculture and wastewater continue to harm ecosystems, reduce agricultural production, and cause eutrophication and acidification. It is anticipated that pollution will significantly rise over the ensuing decades that directly affects human health and has an impact on ecosystems, soil, water, and air. Thus, increasing pollution will grow the demand for discrete analyzers in the market.

Cross-contamination and detection issues caused by frequent washing and reuse of cuvettes or by cleaning the liquid channel inside a flowcell are eliminated when using disposable cuvettes. This advantage of discrete analyzers results in the high usage of discrete analyzers.

The government’s goal is to broaden the scope of pollution monitoring, not to replace or displace current laboratories. The discrete analyzer technique will contribute to expanding the reach of environmental laboratories.

Companies involved in the global discrete analyzers market are actively working to improve their competitiveness through new product introductions, business expansion, regulatory clearances, partnerships, and agreements with both established and emerging competitors.

Acquisitions and mergers significantly accelerate a manufacturer’s ability to capture a significant share of the market. Some of the recent instances of this trend are:

Key Takeaways from Market Study

Discrete analyzers system held a 6% market share in the product segment of the global discrete analyzers market in 2022, owing to excellent product quality and accuracy.
Bench top discrete analyzers accounted for 4% of the global market share in the modality segment of the global discrete analyzers market in 2022. This is because these analyzers perform different tests quickly on a variety of samples.
Environmental testing labs segment held a share of 3% of the end-user category of the global discrete analyzers market in 2022, due to the serious global contamination incidents.
North America held a market share of 4% in 2022, owed to the high prevalence of waterborne diseases.

“Increasing Prevalence of Water Borne Diseases and the Advancements in Terms of Technology used in Water Quality Monitoring is set to Propel Sales of the Discrete Analyzers Market across the Globe,” says an analyst of Future Market Insights.

Interest in Market Trends: Get Detailed Analysis and Insights with Our Comprehensive Report!

Market Competition:

The discrete analyzers market is highly fragmented because of the large number of players in the market both local and international. There is a broad range of products that can be categorized under the discrete analyzers market, making it a broad market. The strategies that are majorly followed by the key players of the discrete analyzers market include product launches and expansions.

In August 2022, Abbott Laboratories, a major U.S. provider of medical technology, is investing 440 million euros in Ireland to create new jobs in Donegal and a sizable new manufacturing facility in Kilkenny.
In Jan 2020, the suPARnostic® TurbiLatex product from ViroGates received regulatory approval (CE-IVD) for use with Siemens Healthineers’ ADVIA® Chemistry XPT System. The suPARnostic® TurbiLatex solution from ViroGates is now available for clinical regular usage in hospitals using ADVIA XPT systems.

Key Companies Profiled:

Thermofisher Scientific Inc.
Seal Analytical
Skalar Analytical B.V.
Chinchilla Scientific
SYSTEA S.p.a
Astoria-Pacific, Inc.
Siemens Industry, Inc.
NECi Superior Enzymes
Abbott Laboratories
Roche Holding AG
KPM Analytics

Key Market Segments Covered in Discrete Analyzers Industry Research:

Product:

Discrete Analyzer System
- <140 Tests Capacity
- 150-200 Tests Capacity
- 201-450 Tests Capacity
- 451-600 and more Tests Capacity
Consumables
- Cuvettes
- Reagents
- Coils
Software

Modality:

Standalone discrete Analyzers
Bench Top Discrete Analyzers

End User:

Waste Water Plants
General Testing Labs
Environmental Testing Labs
Agriculture and Food Testing Labs
Pharmaceutical Companies
Government and Academic Institutes and Laboratories
Contract Research Organization

Region:

North America
Latin America
Europe
South Asia and Pacific
East Asia
Middle East and Africa

About Future Market Insights (FMI)

Contact Us:

Global Medical Device Packaging Market to be Worth USD 65.26 Billion by 2033: Future Market Insights, Inc.

The global medical device packaging market is expected to be worth USD 38.57 billion in 2023, rising to USD 65.26 billion by 2033. The adoption of medical device packaging is expected to surge at a stable CAGR of 6.1% over the forecast period.

The medical device packaging market is experiencing significant growth driven by several key factors. The increasing aging population and the associated rise in chronic diseases are driving the demand for medical devices such as pacemakers, stents, and artificial joints, leading to an increased need for proper packaging to ensure the safety and integrity of these devices.

Advancements in medical technology have also led to the development of new medical devices, requiring manufacturers to invest in packaging solutions to protect them during transportation and storage.

Discover the Full Details in Our Report—Read More Now!

In addition, the growing demand for minimally invasive surgical procedures is driving the need for smaller medical devices and appropriate packaging solutions to ensure safe delivery to the surgical site. Stringent regulations for medical device packaging are also playing a key role in driving demand as governments around the world implement standards to protect the safety and integrity of the devices.

Furthermore, rising awareness about the importance of proper packaging in extending the shelf life of medical devices is also driving demand.

While the adoption of medical device packaging is expected to experience significant growth, manufacturers are also facing several challenges. One of the prominent challenges is meeting stringent regulations and compliance requirements to ensure the safety and integrity of medical devices.

Another challenge is ensuring the compatibility of packaging materials with medical devices to avoid any damage. Managing costs while maintaining high standards of quality is also a significant challenge for manufacturers as they strive to produce packaging solutions at a competitive price while meeting industry standards.

Key Takeaways from the Medical Device Packaging Market:

The paper and paperboard market is predicted to account for USD 14,293.2 million by 2033 and to register a 5.5% CAGR throughout the projection period.
During the projection period, the plastic segment is expected to offer a growth potential of USD 6,620.8 million. In 2022, the boxes sector accounted for about 30% of the market. This category is also predicted to rise at a healthy 5.5% CAGR throughout the projection period.
Folding cartons are expected to represent an incremental potential of USD 1.9 billion over the projection period and to account for more than 21% of the market by 2033.
During the projection period, the medical device packaging sector in the United States is expected to exceed USD 5,067.6 million.
German market is predicted to provide a startling additional opportunity of USD 1,030.4 million, making it an appealing location for both investors and producers.
By 2033, China’s medical device packaging industry is expected to be worth USD 1,270.1 million.

Who is Winning?

Product innovation, market expansion into new markets, strategic alliances and collaborations, and acquisitions are common growth tactics employed by the industry’s leading players. Startups in the market are developing innovative technologies to efficiently label medical devices.

Packaging companies may save validation time and eventually create smaller batch sizes that comply with customer specifications by applying the same processes for identical medical devices with a few minor adjustments. The use of NFC and RFID tags in packaging materials is expected to be promoted by counterfeiting, which is a serious problem with medical supplies.

Key Players

Avery Dennison Corporation
3M Company
E.I. du Pont de Nemours and Company
CCL Industries Inc.
Amcor Limited
Constantia Flexibles Group GmbH
Bemis Company, Inc
Sonoco Company
WestRock Company

Recent Developments in the Market:

Ashfield, a subsidiary of UDG Healthcare plc, announced the development of three business divisions in January 2021, to expand and diversify its healthcare capabilities.
In April 2021, Amcor presented its newest invention, the New AmSkyTM blister system. This innovation has the potential to revolutionize medical packaging sustainability.
In April 2020, Amcor’s ULTRA pouches was certified for steam sterilization at 134°C and vaporized hydrogen peroxide treatment. As a result, the pouches may be used to sterilize reusable medical equipment.

Medical Device Packaging Market by Category

By Material:

Paper and Paperboard
Plastics

By Packaging Format:

Boxes
Folding Cartons
Bags and Pouch
Trays
Inserts and Dividers
Wrapping Films

By End Use:

Surgical
Therapeutic
Diagnostic

By Region:

North America
Latin America
Europe
South Asia and the Pacific
East Asia
The Middle East and Africa

About Future Market Insights (FMI)

Contact Us:

Future Market Insights Inc.
Christiana Corporate, 200 Continental Drive,
Suite 401, Newark, Delaware – 19713, USA
T: +1-845-579-5705
For Sales Enquiries: sales@futuremarketinsights.com
Website: https://www.futuremarketinsights.com
LinkedIn| Twitter| Blogs | YouTube

Consumer Electronics Packaging Market Poised for Steady Growth with 4.5% CAGR Through 2034 | Future Market Insights, Inc.

The global consumer electronics packaging market size is estimated to be around USD 19.6 billion in 2024. It is projected to exhibit a CAGR growth of 4.5% over the forecast period, with an estimated valuation of USD 30.4 billion in 2034.

With the continuous introduction of new electronic devices and gadgets, there is a constant demand for innovative packaging solutions to protect these products during transportation, storage, and display. Additionally, the growing trend of eCommerce and online retailing has fueled the need for durable and secure packaging to ensure safe delivery to consumers’ doorsteps.

Despite its growth potential, the consumer electronics packaging industry faces several challenges that act as restraints to its progress. One significant restraint is the constant pressure to reduce packaging costs while maintaining quality and functionality. This often leads to compromises in material quality and durability, which can impact the protection of electronic devices during transit.

Find Out More—Read the Complete Report for Full Insights!

A significant opportunity for players lies in the development of smart packaging solutions that integrate technology to enhance product functionality and user experience. Furthermore, the increasing adoption of sustainable packaging materials presents an opportunity for companies to align with environmental initiatives and tap into the growing market for eco-friendly solutions.

One notable trend is the increasing use of minimalist packaging designs, characterized by sleek and compact layouts that reduce material usage and environmental footprint. Another trend is the integration of smart packaging technologies, such as RFID tags and NFC chips, to enable product tracking, authentication, and interactive experiences for consumers. Moreover, there is a growing emphasis on biodegradable and compostable packaging materials, driven by consumer preferences for eco-friendly products and brands committed to sustainability.

“The rising demand for personalized and customized packaging offers opportunities for packaging manufacturers to differentiate their products and cater to the unique needs of consumers.” Says Future Market Insights (FMI).

Key Takeaways from the Market Study:

Corrugated boxes hold a dominant share of 23.1% in 2024, providing a cost-effective solution for manufacturers.
Mobile phone packaging marks its dominance with a 24.1% share in 2024.
The consumer electronics packaging industry in the United States is anticipated to rise at a CAGR of 2.4% through 2034.
The consumer electronics packaging industry in the United Kingdom is projected to rise at a CAGR of 4.6% through 2034.
China’s consumer electronics packaging industry is likely to witness expansion at a CAGR of 6.5% through 2034.
Japan’s consumer electronics packaging industry is projected to rise at a CAGR of 3.6% through 2034.
South Korea’s consumer electronics packaging industry is set to expand at a CAGR of 5.6% through 2034.
Europe & USA Consumer Electronics Packaging Market is expected to reach USD 6.4 billion by 2033, growing at a CAGR of 4.8% during the forecast period 2023 to 2033

Competitive Landscape:

The consumer electronics packaging industry includes established giants like Tetra Pak, Amcor, International Paper, and Sealed Air vie for dominance while facing increasing competition from startups. These industry players command a significant market share with their robust infrastructure and diverse offerings, yet they must contend with innovative upstarts focused on customization, sustainability, and cost efficiency.

The sector is characterized by a dynamic interplay between established players and emerging challengers, shaping the landscape with their evolving strategies and market approaches.

Sustainability is emerging as a crucial element in the consumer electronics packaging industry, driven by consumer demand and regulatory pressures. Companies are under increasing pressure to adopt eco-friendly practices and materials, with innovations in sustainability offering a competitive edge.

As the industry expands into emerging markets like China and India, companies face both opportunities and complexities. While these regions offer vast potential, navigating local regulations, preferences, and supply chains requires adaptability and a deep understanding of each industry.

Key Companies in the Market:

DS Smith Plc
Mondi Group
International Paper Company
Sonoco Products Company
Sealed Air Corporation
Huhtamaki Oyj
Smurfit Kappa Group PLC
WestRock Company
UFP Technologies, Inc.
Stora Enso Oyi
Pregis Corporation
Shenzhen Hoichow Packing Manufacturing Ltd.
Dordan Manufacturing Company
Hangzhou Xunda Packaging Co.
Dunapack Packaging Group
JJX Packaging LLC

Recent Developments:

Mondi Group created a novel packaging solution called PerFORMing, which is a paper-based tray that can replace plastic trays in food packing. The product is recyclable, biodegradable, and cuts plastic use by 80%.
Sonoco Products Company announced a new sustainability target of reducing greenhouse gas emissions by 25% by 2025. The corporation also intends to enhance its usage of renewable energy and invest in energy-efficiency initiatives.
Sealed Air Corporation recently introduced a new product line dubbed Korrvu Lok, a compression packaging technology that keeps items in place and minimizes damage during transportation. The solution is intended for eCommerce and omni-channel businesses, and it may minimize packaging material and labor expenses.
Huhtamaki Oyj acquired Jiangsu Hihio-Art Packaging Co. Ltd., a Chinese maker of paper bags, wraps, and folding carton packaging. Huhtamaki’s position in the developing foodservice packaging sector in China and Asia Pacific will be strengthened as a result of the purchase.

Key Segmentations

By Product Type:

Corrugated Boxes
Paperboard Boxes
Thermoformed Trays
Bags & Pouches
Blister Packs & Clamshells
Protective Packaging
Others

By Application:

Mobile Phones
Computers
- Laptops & Tablets
- Desktops & Servers
TVs, DTH & Set-Top boxes
Music Systems
Printers, Scanners & Photocopy Machines
Game Consoles & Toys
Camcorders & Cameras
Electronic Wearable
Digital Media Adapters
Others

By Material Type:

Plastic
- Polyethylene (PE)
- Polypropylene (PP)
- Poly Vinyl Chloride (PVC)
- Polyamide (PA)
- Polyethylene terephthalate (PET)
- Polystyrene (PS)
- Others
Paper & Paperboard
Others

By Region:

North America
Latin America
Europe
East Asia
South Asia
Oceania
Middle East and Africa

About Future Market Insights (FMI)

Contact Us:

Global Salivary Gland Infection Treatment Market Set to Surge to USD 12,300 Million by 2033 registering a CAGR of 9.3%

The global salivary gland infection treatment market is poised for remarkable expansion, with projections indicating a surge to a valuation of USD 12,300 million by 2033. This anticipated growth represents a significant leap from the USD 5,054.79 million recorded in 2023, reflecting a robust compound annual growth rate (CAGR) of 9.3% over the forecast period, according to the latest market research report.

The optimistic outlook for the market is largely driven by the increasing prevalence of salivary gland infections worldwide. As the incidence of these infections continues to rise, the demand for effective treatment options is intensifying. Furthermore, the enhanced availability of advanced pharmaceutical interventions is contributing to the market’s growth trajectory.

Poor oral hygiene, specific underlying health conditions, and the use of certain medications have been identified as critical contributors to the heightened risk of developing salivary gland infections. This acknowledgment has spurred a significant uptick in the demand for innovative and effective treatment solutions. Healthcare providers and pharmaceutical companies are increasingly focused on developing and distributing products and services aimed at diagnosing, treating, and managing these infections efficiently.

The global salivary gland infection treatment market is at the cusp of a transformative phase, fueled by a combination of technological advancements, improved access to healthcare, and an overarching emphasis on preventive oral care. As the market continues to evolve, stakeholders across the healthcare spectrum are poised to witness substantial opportunities for growth and development in the realm of salivary gland infection treatment solutions.

Key Takeaways from the Market Study:

The global Salivary gland infection treatment market is expected to grow with 9.3% CAGR during 2023 to 2033.
By treatment, medication is expected to hold 55% of the market share in 2023 for Salivary gland infection treatment market.
North America is expected to possess 49% market share for Salivary gland infection treatment market in 2023.
Europe Salivary gland infection treatment market size is expected to possess 43% market share in 2023.

“With a growing awareness of the importance of oral health and an increasing incidence of salivary gland infections, this market is poised for continued growth and innovation in the years to come.” states an FMI analyst

Increased Market Attention: Delve into Detailed Trends and Analysis with Our Report!

Competitive Landscape:

Key players in the salivary gland infection treatment market are AbbVie Inc., Allergan, AstraZeneca, FUJIFILM Holdings Corporation, GlaxoSmithKline plc., Johnson & Johnson Services, Merck & Co., Inc., Pfizer Inc., Siemens Healthcare GmbH and Novartis AG

Pfizer Inc, a key player in the salivary gland infection market is focusing on investing in research and development for testing medications under clinical trials.
Siemens Healthcare GmbH, another key player in the salivary gland infection market is focusing on commercializing medications owing to the commonality of the ailment.

Key Segments Profiled in the Salivary Gland Infection Treatment Industry Survey:

Diagnosis:

MRI
CT Scan
PET Scan
Endoscopy
Biopsy

Treatment:

Medication
Surgery

Distribution Channel:

Hospital Pharmacy
Retail Pharmacy
Online Pharmacy

End Users:

Hospitals
Clinical Laboratories
Ambulatory Surgical Centres

Region:

North America
Latin America
Europe
South Asia
East Asia
Oceania
Middle East and Africa(MEA)

About Future Market Insights (FMI)

Contact Us:

Global Sandhoff Disease Therapeutics Market to Witness Significant Growth, Projected to Reach USD 17.91 Million by 2033

In a recent comprehensive analysis by Future Market Insights, the global sandhoff disease therapeutics market is anticipated to undergo substantial growth over the next decade. Currently valued at USD 10 million, the market is projected to achieve a notable valuation of USD 17.91 million by 2033, reflecting a compound annual growth rate (CAGR) of 6% during the forecast period from 2023 to 2033.

Sandhoff disease, a rare genetic disorder with an incidence rate of approximately 1 in 1,000,000 individuals globally, is characterized by the accumulation of specific fats in the brain and other organs. This accumulation leads to progressive neurological damage, making the condition particularly challenging for those affected.

This significant growth in the global Sandhoff disease therapeutics market underscores the importance of innovative solutions to address the unmet medical needs of patients. As awareness about rare diseases continues to grow and advancements in medical technology expand, there is an increasing focus on developing therapies that can improve the quality of life for individuals affected by Sandhoff disease.

The findings of the analysis provide valuable insights for stakeholders in the healthcare sector, including pharmaceutical companies, research institutions, and policymakers. By understanding the evolving landscape of the Sandhoff disease therapeutics market, stakeholders can strategize and allocate resources effectively to drive innovation and enhance patient care.

Key Takeaways from the Market Study:

From 2018 to 2022, the Sandhoff disease therapeutics market grew at a CAGR of 4%.
The global Sandhoff disease therapeutics market is expected to grow with a 6% CAGR during 2023 to 2033.
As of 2033, the sandhoff disease therapeutics Market is expected to reach USD 17.91 Million.
According to the FMI analysis, hospitals account for the largest market share.
North America is expected to possess 40% market share for the Sandhoff Disease Therapeutics market.
The Asia Pacific market is predicted to increase significantly throughout the forecast period, with a share of 20%.

“A series of international level collaborations involving healthcare stakeholders across various institutional settings are fueling further clinical trials and research studies dedicated to discovering Sandhoff disease therapeutics.” says an FMI analyst

Soaring Demand for Market Information: Uncover Detailed Trends and Insights in Our Report!

Market Competition:

Key players in the market include pharmaceutical companies such as Bioasis Technologies Inc, Nuo Therapeutics Inc., Sio Gene Therapies, Inc., INTRABIO IRELAND LIMITED, Sanofi, ROIVANT SCIENCES LTD, Azafaros, Polaryx Therapeutics, Abbott Medtronic, and Merck & Co., Inc. along with healthcare providers and technology companies among other global players.

In November 2020, Axovant Gene Therapies Ltd., a company developing gene therapies, announced that the FDA has cleared its Investigational New Drug Application to start a registrational study of AXO-AAV-GM2 gene therapy for Tay-Sachs and Sandhoff diseases.
AXO-AAV-GM2 is the first gene therapy to receive IND clearance for these diseases. The FDA letter confirms that all issues related to the clinical hold have been resolved. This marks a significant moment for the GM2 gangliosidosis community and is the second IND clearance for Axovant’s gene therapy pipeline in the last year, with the first being AXO-AAV-GM1 for GM1 gangliosidosis.

More Insights Available:

FMI, in its new offering, presents an unbiased analysis of the global Sandhoff Disease Therapeutics market, presenting historical analysis from 2018 to 2022 and forecast statistics for the period of 2023 to 2033.

The study reveals essential insights on the basis of Type, Therapy, End-Users and Region.

Key Segments Profiled in the Sandhoff Disease Therapeutics Industry Survey:

Therapy:

Gene Therapy
Enzyme Replacement Therapy
Stem Cell Therapy

Type:

Acute infantile Sandhoff disease
Subacute juvenile Sandhoff disease
Late-onset Sandhoff disease

End-Users:

Hospitals
Homecare
Specialty Clinics

Region:

North America
Latin America
Europe
East Asia
South Asia
Oceania
Middle East & Africa

About Future Market Insights (FMI)

Contact Us: